Where are the Investors Headed: Complementary Research on Ladder Capital, New York REIT, J.G. Wentworth, Pain Therapeutics and MYOS Corp.

May 15, 2015, 08:20 ET from Analysts Review

NEW YORK, May 15, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom. 

Moments ago, Analysts Review released new research updates concerning several important developing situations including Ladder Capital Corp (NYSE: LADR), New York REIT, Inc. (NYSE: NYRT), The J.G. Wentworth Company (NYSE: JGW), Pain Therapeutics Inc. (NASDAQ: PTIE), and MYOS Corporation (NASDAQ: MYOS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.    

To access our full PDF reports on a complementary basis, please visit the links below.


Today's update concerns the following companies:


Full PDF Download Links (you may have to copy and paste the following links into your browser):

LADR Research Report: ( http://get.analystsreview.com/pdf/?c=Ladder%20Capital&d=15-May-2015&s=LADR ),

NYRT Research Report: ( http://get.analystsreview.com/pdf/?c=New%20York%20REIT&d=15-May-2015&s=NYRT ),

JGW Research Report: ( http://get.analystsreview.com/pdf/?c=J.G.%20Wentworth&d=15-May-2015&s=JGW ),

PTIE Research Report: ( http://get.analystsreview.com/pdf/?c=Pain%20Therapeutics&d=15-May-2015&s=PTIE ),

MYOS Research Report: ( http://get.analystsreview.com/pdf/?c=MYOS%20Corp.&d=15-May-2015&s=MYOS ).



Analyst Update: Financial and Operational Results  and Clinical Trials 

U.S. stocks closed higher on Thursday, recovering from a sequence of slight losses over the week. The rally came despite unexpected drop in both weekly jobless claims and headline inflation figure. The NASDAQ Composite closed at 5,050.79, up 1.39%, the S&P 500 jumped 1.08%, to 2,121.10, and the Dow Jones Industrial Average ended the session 1.06% higher, at 18,252.24. European stocks surged sharply higher on Thursday after the European Central Bank's president reaffirmed its commitment to continue massive stimulus program for the Eurozone. Germany's DAX 30 advanced 1.84%, France's CAC 40 gained 1.36%, and London's FTSE 100 closed 0.34% higher on Thursday. Meanwhile, Asian markets were once again mixed on Thursday. The Shanghai Composite and Hong Kong's Hang Seng posted modest gains, while Japan's Nikkei fell on Thursday.

On May 6, 2015, Ladder Capital Corp. announced its financial and operational results for the first quarter of 2015. The Company reported a net income of $18 million for the quarter. The Company's Core Earnings, which is a non-GAAP measure, was $48 million for Q1 2015. On a per share basis, the net earnings worked out to $0.18 whereas Core EPS, a non-GAAP measure, was $0.48 for Q1 2015.

New York REIT, Inc. (NYR) announced its financial and operating results for the first quarter of 2015 on May 11, 2015. The Company recorded Same Store Cash Net Operating Income for the first quarter 2015 of $26.8 million versus $23.9 million in Q1 2014, a year-on-year increase of 12%. The Company's portfolio occupancy was 95.2% as of March 31, 2015, compared to 94.9% sequentially.

The J.G. Wentworth Company announced its financial and operational results for the first quarter of 2015 on May 11, 2015. The Company reported an increase in its total receivables balance purchases to $260.8 million for Q1 2015 versus $260.6 million in Q1 2014. The Company announced its intention to enter mortgage category with the acquisition of WestStar Mortgage, Inc. on March 6, 2015.

On May 12, 2015, Pain Therapeutics, Inc. announced top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse.

On May 11, 2015, MYOS Corp. announced the initiation of a dose response clinical study of Fortetropin® in modestly resistance trained subjects. The study will be led by, Jacob Wilson, Ph.D, CSCS*D, Professor of Health Sciences and Human Performance at the University of Tampa, and will examine the effects of Fortetropin® supplementation on plasma myostatin levels at various dosing levels.


About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.


Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review